This research develops an oral disintegrating tablet formulation for tolvaptan, suggesting a new alternative to the commercial product.
A new SD formulation with increased solubility and dissolution rate compared with pure tolvaptan was developed. The developed ODTs may be an alternative to the current commercial product.
No takes yet. Share an insight, caveat, or question.
Kara et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: